BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1]
URL: https://www.wjgnet.com/1007-9327/full/v15/i1/1.htm
Number Citing Articles
1
Changlong Hou, Baizhu Xiong, Lei Zhou, Yipeng Fei, Changgao Shi, Xianhai Zhu, Tao Xie, Yulin Wu. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinomaBMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12144-6
2
Beichuan Pang, Bangyou Zuo, Liang Huang, Xinyu You, Tao Liu, Jianjie Hao, Chengxiang Yuan, Chong Yang, Wan Yee Lau, Yu Zhang. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinomaInternational Immunopharmacology 2024; 137: 112492 doi: 10.1016/j.intimp.2024.112492
3
Junning Liu, Guangnian Zhang, Linfeng Yang, Duan Yan, Jiahui Yu, Song Wei, Jijiang Li, Pengsheng Yi. Salvage liver transplantation versus curative treatment for patients with recurrent hepatocellular carcinoma: A systematic review and meta-analysisEuropean Journal of Surgical Oncology 2024; 50(7): 108427 doi: 10.1016/j.ejso.2024.108427